What is the recommended management of Kawasaki disease in children?

Management of Kawasaki Disease

All children diagnosed with Kawasaki disease should receive intravenous immunoglobulin (IVIG) 2 g/kg as a single infusion plus aspirin within the first 10 days of illness onset 1, 2.

Acute Phase Treatment (First 10 Days)

Primary Therapy

IVIG Administration:

• Dose: 2 g/kg as a single infusion (evidence level A) 2
• Timing: Must be given within first 10 days of fever onset to reduce coronary artery aneurysm risk from ~25% to <5% 3
• Higher peak serum IgG levels correlate with better outcomes; lower levels associate with persistent fever and coronary abnormalities 2

Aspirin Regimen:

• Acute phase: 80-100 mg/kg/day divided in 4 doses during active inflammation 2
• Duration of high-dose: Continue until afebrile for 48-72 hours, OR until day 14 of illness plus 48-72 hours after fever resolution 2
• Transition to low-dose: 3-5 mg/kg/day once fever resolves 2
• Duration of low-dose: Continue until 6-8 weeks after onset if no coronary changes; continue indefinitely if coronary abnormalities develop (evidence level B) 2

Critical caveat: Avoid ibuprofen in children with coronary aneurysms as it antagonizes aspirin's irreversible platelet inhibition 2.

IVIG-Resistant Disease Management

Definition: Persistent or recrudescent fever ≥36 hours after completing first IVIG infusion 1

Second-Line Options (in order of recommendation strength):

1. Second IVIG infusion (2 g/kg) - Most reasonable first choice (Class IIa, Level B) 1

2. High-dose pulse methylprednisolone - Alternative to second IVIG or for recurrent fever after additional IVIG 1

   • Dose: 20-30 mg/kg IV for 3 days
   • May include subsequent oral prednisone taper (Class IIb, Level B)

3. Extended corticosteroid course - 2-3 week tapering prednisolone/prednisone with IVIG 2 g/kg and aspirin for recurrent fever (Class IIb, Level B) 1

   • Japanese RAISE study demonstrated reduced coronary artery dilation in high-risk patients with adjunctive corticosteroids 4

4. Infliximab (5 mg/kg) - Alternative to second IVIG or corticosteroids (Class IIb, Level C) 1

   • Network meta-analysis showed medium-dose IVIG + aspirin + infliximab had shortest fever duration and smallest CAL incidence in initial-stage KD 5
   • Significantly improved resolution vs. high-dose IVIG alone in refractory KD (OR=0.20) 5

Highly Refractory Disease (Third-Line):

1. Cyclosporine - For patients failing second IVIG, infliximab, or steroids (Class IIb, Level C) 1

   • Network meta-analysis showed high-dose IVIG + cyclosporine had smallest CAL incidence in refractory KD 5
   • Well-tolerated with few serious adverse events 1

2. Other options for exceptional cases:

   • Anakinra (IL-1 receptor antagonist) - case reports show success 1
   • Plasma exchange - reserve for patients failing all medical therapies due to risks 1
   • Cytotoxic agents (cyclophosphamide) with oral steroids - for particularly refractory cases 1

Coronary Artery Thrombosis Management

If acute coronary occlusion occurs, target multiple coagulation steps simultaneously 2:

Antiplatelet Therapy:

• Continue aspirin 3-5 mg/kg/day
• Add clopidogrel 1 mg/kg/day (max 75 mg/day) - preferred over dipyridamole based on adult data 2

Anticoagulation:

• Unfractionated heparin: Load 50 U/kg, then 20 U/kg/hour IV; adjust to aPTT 60-85 seconds 2
• Low-molecular-weight heparin: Treatment dose varies by age (infants <12 months: 3 mg/kg/day divided q12h; children: 2 mg/kg/day divided q12h); adjust to anti-Xa 0.5-1.0 U/mL 2

Thrombolytic Therapy (evidence level C):

• Tissue plasminogen activator (tPA): Bolus 1.25 mg/kg, then 0.1-0.5 mg/kg/hour for 6 hours - achieves better coronary patency than streptokinase 2
• Abciximab (glycoprotein IIb/IIIa inhibitor): Bolus 0.25 mg/kg, then 0.125 μg/kg/min for 12 hours - reduced-dose thrombolytic with abciximab as effective as full-dose with lower reocclusion rates 2

Mechanical Intervention:

• Immediate coronary angioplasty or stent placement effective in adults and used in small number of children 2

Special Considerations

Reye Syndrome Prevention:

• Annual influenza vaccine mandatory for children on long-term salicylates 2
• Weigh theoretical varicella vaccine risks against known wild-type varicella risks in children on salicylates 2
• Parents must contact physician immediately if child develops or is exposed to influenza or varicella 2

Kawasaki Disease Shock Syndrome (KDSS):

• Occurs in ~7% of cases 1
• Manifests as hypotension requiring volume expanders, vasopressors, or ICU transfer
• Shock often moderate with low lactate; responds to diuretics and vasopressors 1

High-Risk Patients Requiring Aggressive Management:

• IVIG-resistant patients
• Young infants
• Males
• Highly inflamed patients
• Those with coronary changes at diagnosis 3